Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …

BACKGROUND Immunotherapies that target the interaction of programmed death 1 (PD-1)
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …

BACKGROUND: Phase 1-2 trials involving patients with resectable, macroscopic stage III
melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …

In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with
continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic …

The gut microbiota shapes the response to immune checkpoint inhibitors (ICIs) in cancer,
however dietary and geographic influences have not been well-studied in prospective trials …

Abstract PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …

Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC)
results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non …

Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …